CGI Pharmaceuticals, Inc.

Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million

Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million

June 25, 2010

Deal to Broaden Gilead's Research Expertise into Kinase Biology and Chemistry

Ensemble Therapeutics Corporation

Ensemble Therapeutics Presents Data at American Chemical Society National Meeting

Ensemble Therapeutics Presents Data at American Chemical Society National Meeting

August 24, 2010

Progress with Macrocyclic-Based Drug Discovery Platform Highlighted

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society (ACS) National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.

Poster Presentations:

Flagship's David Berry Quoted in article in Technology Review: Death Knell for Some Clean Tech Companies

Flagship's David Berry Quoted in article in Technology Review: Death Knell for Some Clean Tech Companies

August 18, 2010

Partner David Berry, associated with several of Flagship's companies in the Sustainability sector. He was recently interviewed for a TR article on the potentials for a carbon cap-and-trade system in the US.

 

Carbon Design Systems

RTL models fly at KHz speeds

RTL models fly at KHz speeds

January 5, 2004

By Clive Maxfield
EEdesign.com
January 05, 2004 (8:56 PM EST)

Morphotek, Inc.

Morphotek announces research and development agreement with the National Cancer Institute for the development of antibodies for the treatment of pancratic, ovarian and lung cancer

Morphotek announces research and development agreement with the National Cancer Institute for the development of antibodies for the treatment of pancratic, ovarian and lung cancer

January 12, 2004

Exton, PA, January 12, 2004 - Morphotek® Inc. announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by researchers at the NCI. Morphotek will apply its proprietary MORPHODOMA® antibody technology to the development of novel antibodies for use in the treatment of pancreatic, ovarian and lung cancers.

Carbon Design Systems

Carbon on the move with additional $10M funding

Carbon on the move with additional $10M funding

January 13, 2004

Matrix leads second round, former ViewLogic CEO joins board

Affinnova, Inc.

Affinnova Appoints Sporting Goods Industry Veteran and Former Reebok CEO Robert Meers to Executive Board

Affinnova Appoints Sporting Goods Industry Veteran and Former Reebok CEO Robert Meers to Executive Board

January 20, 2004

CAMBRIDGE, MASS. - January XX, 2003 - Affinnova, Inc., a leading provider of product design and development solutions, today announced the appointment of Robert Meers to its Executive Board. Mr. Meers, a proven corporate leader and consumer goods visionary with over 30 years of International brand building experience, will assist in guiding Affinnova's strategic growth initiatives.

CGI Pharmaceuticals, Inc.

Cellular Genomics Raises $22.3 Million in First Close of Series C Financing

Cellular Genomics Raises $22.3 Million in First Close of Series C Financing

January 21, 2004

BRANFORD, Conn., Jan. 21 /PRNewswire/ -- Cellular Genomics Inc. (CGI), a chemical genetics based drug discovery and development company, today announced that it has raised $22.3 million in the initial close of a Series C private equity financing. This Series C Round is being led by Lilly BioVentures, and has been joined by new investors Coastview Capital and Emerging Technology Partners, as well as existing investors including Connecticut Innovations, Flagship Ventures, MPM Capital, and Vector Fund Management.

BG Medicine, Inc.

Beyond Genomics and GlaxoSmithKline Announce Partnership to Apply Systems Biology to Metabolic Diseases

Beyond Genomics and GlaxoSmithKline Announce Partnership to Apply Systems Biology to Metabolic Diseases

January 28, 2004

Waltham, Mass. and London, U.K. - January 28, 2004 - Beyond Genomics, Inc. (BG) and GlaxoSmithKline (GSK) announced today that they have entered into a research collaboration, option and license agreement in the area of systems biology for the purpose of drug discovery and development in metabolic diseases. This follows a successful pilot relationship between the companies that began in December 2002 and involved the use of BG's proprietary Systems Biology platform to elucidate disease pathways and identify biomarkers of disease state and drug response.

CGI Pharmaceuticals, Inc.

Career straddles clinical, research roles

Career straddles clinical, research roles

February 2, 2004

By Dyke Hendrickson, Mass High Tech, February 2, 2004

If a biotech executive were preparing to approach the Food and Drug Administration with a new drug application, it would be useful for him to be knowledgeable about federal regulation as well as medical science.

Enter Dr. Louis Matis. He is a medical doctor, and also a former physician/researcher with both the FDA and the National Institutes of Health.